Hyloris Pharmaceuticals's revenue for the
six
months ended in Dec. 2023 was €1.65 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €2.81 Mil.
Hyloris Pharmaceuticals's Revenue per Share for the
six
months ended in Dec. 2023 was €0.06.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.10.
Warning Sign:
Hyloris Pharmaceuticals SA revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Hyloris Pharmaceuticals was -7.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 132.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 127.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, Hyloris Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 210.70% per year. The lowest was -3.90% per year. And the median was 166.05% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hyloris Pharmaceuticals's Revenue
For the Biotechnology subindustry, Hyloris Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's Revenue falls into.
Hyloris Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Hyloris Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Hyloris Pharmaceuticals (XBRU:HYL) Business Description
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBRU:HYL has been successfully added to your 